• Ultac indications
• Uses of Ultac in details
• Ultac description
• Ultac dosage
• Ultac interactions
• Ultac side effects
• Ultac contraindications

What is Ultac?

Ultac is in a group of drugs called histamine-2 blockers. Ultac works by reducing the amount of acid your stomach produces.

Ultac is used to treat and prevent ulcers in the stomach and intestines. It also treats conditions in which the stomach produces too much acid, such as Zollinger-Ellison syndrome. Ultac also treats gastroesophageal reflux disease (GERD) and other conditions in which acid backs up from the stomach into the esophagus, causing heartburn.

Ultac may also be used for purposes not listed in this medication guide.

Ultac indications

Ultac Tablets, USP are indicated in:

1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ultac in uncomplicated duodenal ulcer for periods of more than 8 weeks.

2.Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year.

3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis).

4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated.

Studies available to date have not assessed the safety of Ultac in uncomplicated, benign gastric ulcer for periods of more than 6 weeks.

5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year.

6.Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ultac Tablets, USP 150 mg twice daily.

7.Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ultac Tablets, USP 150 mg 4 times daily.

8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks.

Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.

How should I use Ultac?

Use Ultac tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• If you are using Ultac tablets to treat symptoms, take it by mouth with or without food.
• If you are using Ultac tablets to prevent symptoms, take it by mouth 30 to 60 minutes before eating food or drinking beverages that cause your symptoms.
• Take Ultac tablets with a full glass of water (8 oz/240 mL).
• If you also take itraconazole or ketoconazole, ask your doctor or pharmacist how to take it with Ultac tablets.
• Do not take other antacids while you are using Ultac tablets without first checking with your doctor.
• Continue to take Ultac tablets even if you feel well. Do not miss any doses.
• If you miss a dose of Ultac tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Ultac tablets.

Uses of Ultac in details

Ultac is used to treat ulcers of the stomach and intestines and prevent them from coming back after they have healed. This medication is also used to treat certain stomach and throat (esophagus) problems (such as erosive esophagitis, gastroesophageal reflux disease-GERD, Zollinger-Ellison syndrome). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as cough that doesn't go away, stomach pain, heartburn, and difficulty swallowing. Ultac belongs to a class of drugs known as H2 blockers.

This form of Ultac is given by injection and is used for short-term treatment of these conditions when you cannot take this medication by mouth. Your doctor should switch you to taking this medication by mouth when possible.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

This medication may also be used to prevent ulcers caused by a certain class of drugs known as nonsteroidal anti-inflammatory drugs-NSAIDs (such as ibuprofen, naproxen). It may also be used to prevent stomach/intestinal bleeding.

How to use Ultac injection

Read the Patient Information Leaflet if available from your pharmacist before you start using Ultac and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

This medication is given by injection into a vein or muscle as directed by your doctor. Premixed bags should only be given into a vein. The dosage and length of treatment are based on your medical condition and response to treatment. In children, the dosage may also be based on body weight.

If you are using this medication at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.

Tell your doctor if your condition does not improve or if it worsens.

Ultac description

An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as cimetidine and Ultac. It is generally well tolerated by patients.

Ultac dosage

Ultac Dosage

Generic name: Ultac HYDROCHLORIDE 150mg

Dosage form: tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

• adults and children 12 years and over:
• to relieve symptoms, swallow 1 tablet with a glass of water
• to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn
• can be used up to twice daily (do not take more than 2 tablets in 24 hours)
• children under 12 years: ask a doctor

More about Ultac (Ultac)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Interactions
• 0 Reviews - Add your own review/rating

Consumer resources

• Other brands: Zantac, Zantac 150, Zantac 300, Zantac 75, More (4) »

Professional resources

• Ultac (FDA)
• Ultac Hydrochloride (AHFS Monograph)

Related treatment guides

• Duodenal Ulcer
• Duodenal Ulcer Prophylaxis
• Erosive Esophagitis
• Gastric Ulcer Maintenance Treatment
• Gastrointestinal Hemorrhage
• More (7) »

Ultac interactions

See also:
What other drugs will affect Ultac?

In an application with antacids may decrease absorption of Ultac.

In an application of Ultac Dong-il with anticholinergics may be in breach of memory and attention in elderly patients.

Probably that histamine H2-blockers reduce receptor ulcerogenic action of NSAIDs on the gastric mucosa.

In an application with warfarin may decrease clearance of warfarin. There is one case of gipoprotrombinemiey and bleeding in patients receiving warfarin.

In an application with bismuth tripotassium dicitrate may increase unwanted absorption of bismuth, with glyburide - described the cases of hypoglycemia, with ketoconazole, itraconazole - decreased absorption of ketoconazole, itraconazole.

In an application with metoprolol may increase the plasma concentrations and increased AUC and T1 / 2 of metoprolol.

In an application with sucralfate in high doses (2 g) possible violation of the absorption of Ultac.

In an application Ultac Dong-il with procainamide may be decrease excretion of procainamide by the kidneys which leads to an increase in its concentration in blood plasma.

There is a data of increased absorption of triazolam in its simultaneous application, apparently due to changes in pH of gastric contents under the influence of Ultac.

Probably that while the application with phenytoin may increase the concentration of phenytoin in plasma and increased risk of toxicity.

In an application with furosemide moderately expressed increasing the bioavailability of furosemide.

There is a described case of ventricular arrhythmias (bigeminy) with simultaneous application of quinidine, with cisapride - described a case of cardiotoxicity.

It can not be excluded some increase in cyclosporine concentration in blood plasma in its simultaneous application with Ultac.

Ultac side effects

See also:
What are the possible side effects of Ultac?

The following have been reported as events in clinical trials or in the routine management of patients treated with Ultac Tablets, USP. The relationship to therapy with Ultac Tablets, USP has been unclear in many cases. Headache, sometimes severe, seems to be related to administration of Ultac Tablets, USP.

Central Nervous System: Rarely, malaise, dizziness, somnolence, insomnia, and vertigo. Rare cases of reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients. Rare cases of reversible blurred vision suggestive of a change in accommodation have been reported. Rare reports of reversible involuntary motor disturbances have been received.

Cardiovascular: As with other H2-blockers, rare reports of arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats.

Gastrointestinal: Constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, and rare reports of pancreatitis.

Hepatic: There have been occasional reports of hepatocellular, cholestatic, or mixed hepatitis, with or without jaundice. In such circumstances, Ultac should be immediately discontinued. These events are usually reversible, but in rare circumstances death has occurred. Rare cases of hepatic failure have also been reported. In normal volunteers, SGPT values were increased to at least twice the pretreatment levels in 6 of 12 subjects receiving 100 mg four times daily intravenously for 7 days, and in 4 of 24 subjects receiving 50 mg four times daily intravenously for 5 days.

Musculoskeletal: Rare reports of arthralgias and myalgias.

Hematologic: Blood count changes (leukopenia, granulocytopenia, and thrombocytopenia) have occurred in a few patients. These were usually reversible. Rare cases of agranulocytosis, pancytopenia, sometimes with marrow hypoplasia, and aplastic anemia and exceedingly rare cases of acquired immune hemolytic anemia have been reported.

Endocrine: Controlled studies in animals and man have shown no stimulation of any pituitary hormone by Ultac Tablets, USP and no antiandrogenic activity, and cimetidine-induced gynecomastia and impotence in hypersecretory patients have resolved when Ultac Tablets, USP have been substituted. However, occasional cases of gynecomastia, impotence, and loss of libido have been reported in male patients receiving Ultac Tablets, USP, but the incidence did not differ from that in the general population.

Rare cases of breast symptoms and conditions, including galactorrhea and gynecomastia, have been reported in both males and females.

Integumentary: Rash, including rare cases of erythema multiforme. Rare cases of alopecia and vasculitis.

Respiratory: A large epidemiological study suggested an increased risk of developing pneumonia in current users of histamine-2-receptor antagonists (H2RAs) compared to patients who had stopped H2RA treatment, with an observed adjusted relative risk of 1.63 (95% CI, 1.07 to 2.48). However, a causal relationship between use of H2RAs and pneumonia has not been established.

Other: Rare cases of hypersensitiviy reactions (e.g., bronchospasm, fever, rash, eosinophilia), anaphylaxis, angioneurotic edema, acute interstitial nephritis, and small increases in serum creatinine.

Ultac contraindications

See also:
What is the most important information I should know about Ultac?

Hypersensitivity to Ultac or any component of the formulation

OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food, vomiting with blood, or bloody or black stools, allergic to Ultac or other acid reducers. Do not use with other acid reducers. Do not use 150 mg tablet with kidney disease without medical advice.

Documentation of allergenic cross-reactivity for histamine H antagonists is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Active ingredient matches for Ultac:

Ranitidine in Australia.

Unit description / dosage (Manufacturer)	Price, USD
ULTAC Capsule/ Tablet / 300mg / 10 units (Cipla)	$ 0.44
ULTAC Capsule/ Tablet / 150mg / 10 units (Cipla)	$ 0.23
Ultac 150mg TAB / 10	$ 0.06
Ultac 300mg TAB / 10	$ 0.10
25 mg x 2ml	$ 0.03
150 mg x 10's	$ 0.06
300 mg x 10's	$ 0.10
Injectable; Injection; Ranitidine 12.5 mg / ml
Tablets; Oral; Ranitidine 150 mg
Tablets; Oral; Ranitidine 300 mg
Ultac 150 mg Tablet	$ 0.02
Ultac 300 mg Tablet	$ 0.04
Ultac 50 mg Injection	$ 0.02
Ultac 25mg INJ / 2ml	$ 0.03
ULTAC 25MG INJECTION 1 vial / 2 ML injection each (Cipla Ltd)	$ 0.04
ULTAC inj 25 mg x 2ml (Cipla)	$ 0.03
ULTAC tab 150 mg x 10's (Cipla)	$ 0.06
ULTAC tab 300 mg x 10's (Cipla)	$ 0.10
Ultac 25mg Injection (Cipla Ltd)	$ 0.02
List of Ultac substitutes (brand and generic names):
Ulsaven (Mexico)
Dragee; Oral; Ranitidine Hydrochloride 75 mg (Collins)
Ultak (Latvia, South Africa)
Ulticer (Hong Kong)
Ulticer 7 Blister (Medreich)
Ulticer 150 mg x 2 x 10's (Medreich)
Ulticer 150 mg x 10 x 10's (Medreich)
Ulticer tab 150 mg 10 x 10's (Medreich)
Ulticer tab 150 mg 2 x 10's (Medreich)
Ultidin (Colombia)
Ultidine
Ultradin (Bangladesh)
Ultran (Mexico)
Injectable; Injection; Ranitidine Hydrochloride 10 mg / ml (Randall)
Injectable; Injection; Ranitidine Hydrochloride 25 mg / ml (Randall)
Tablet; Oral; Ranitidine 150 mg (Randall)
Tablets; Oral; Ranitidine 150 mg (Randall)
Ulzim (Philippines)
Ulzim 150 mg x 100's (Medhaus)
Ulzim FC tab 150 mg 100's (Medhaus)
Umaren (Hungary)
Umaren 150 mg (Hungary)
Umaren 300 mg (Hungary)
Underacid (Spain)
Unitac (Bangladesh)
Unitin (Mexico)
Tablet; Oral; Ranitidine Hydrochloride 150 mg (Unipharm)
Tablet; Oral; Ranitidine Hydrochloride 300 mg (Unipharm)
Tablets; Oral; Ranitidine Hydrochloride 150 mg (Unipharm)
Tablets; Oral; Ranitidine Hydrochloride 300 mg (Unipharm)
Up and Up Acid Reducer
Up and Up Acid Reducer tablet 200 mg/1 (Target Corporation (US))
Uphatac (Vietnam)
Uphatac 150 mg x 10 Blister xeГ№ x 10 Tablet
Uphatac 300 mg x 10 Blister xeГ№ x 10 Tablet
Urantac (South Korea)
Urgis (Argentina)
Utac (Thailand)
Utidine (Taiwan)
Velrid M
Velrid M 150+200 Tablet (Shreeyam Health Care)	$ 0.02
Veran
Veran 300 mg Tablet (Vega Pharma)	$ 0.01
Veran 150 mg Tablet (Vega Pharma)	$ 0.00
Verlost (Ethiopia, Greece)
Vermispas
Vermispas 150+10 Tablet (Vermilion Healthcare Pvt Ltd)	$ 0.02
Vesyca (Malaysia, Taiwan)
Vesyca 150 mg x 10's x 50 (Ysp)
Vesyca 25 mg/1 mL x 2 mL x 50's (Ysp)
Vesyca 150 mg x 50's (Ysp)
Vesyca 150 mg x 50 x 10's (Ysp)
Vesyca 150 mg x 500's (Ysp)
See 2895 substitutes for Ultac

References

1. PubChem. "ranitidine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
2. DrugBank. "ranitidine". http://www.drugbank.ca/drugs/DB00863 (accessed September 17, 2018).
3. DTP/NCI. "ranitidine: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Ultac are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ultac. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 28 here

Information checked by Dr. Sachin Kumar, MD Pharmacology